Regencell Bioscience Holdings Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$4,301,837 over the previous period. Total operating expenses were $3,991,138.

Profit Margin

Regencell Bioscience Holdings Limited (NASDAQ:RGC): Profit margin
2012 2.82B 144.8M 5.13%
2013 3.03B 157.7M 5.19%
2015 2.99B 105.6M 3.53%
2016 3.19B 170.4M 5.33%
2019 0 -390.99K
2020 0 -812.37K
2021 0 -1.34M
2022 0 -7.42M
2023 0 -5.87M
2024 0 -4.30M

RGC Income Statement (2013 – 2024)

2024 2023 2022 2021 2020 2019 2017 2015 2013 2013
Revenue
Revenue
0000003.19B2.99B3.03B2.82B
Cost of revenue
745.58K769.68K604.39K26.45K9.51K01.22B111M111M101M
Gross profit
-745.58K-769.68K-604.39K-26.45K-9.51K01.97B2.87B2.92B2.72B
Operating exp.
Research and development
1.06M1.58M2.51M438.32K386.23K228.22K0000
Selling and marketing
0262.66K25.27K1.57K114.20K3.63K0000
Total operating expenses
3.99M6.27M7.61M1.38M812.37K390.99K1.62B1.19B1.15B1.05B
Operating income
-4.73M-6.27M-7.61M-1.38M-812.37K-390.99K344.2M306.4M339.8M334.2M
Other income (expenses), net
373.50K211.34K23.21K34.61K00-62.5M-127.8M-75.2M-98.3M
Income before tax
-4.36M-6.06M-7.59M-1.34M-812.37K-390.99K281.7M178.6M264.6M235.9M
Income tax expense
312.12K-191.19K-171.82K0-1-390111.2M73.4M107M91.2M
Net income
-4.30M-5.87M-7.42M-1.34M-812.37K-390.99K170.4M105.6M157.7M144.8M
Earnings per share
Basic EPS
-0.33-0.45-0.57-0.11-0.06-0.031.090.681.020.94
Diluted EPS
-0.33-0.45-0.57-0.11-0.06-0.031.090.681.010.93
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData source